145 related articles for article (PubMed ID: 19275521)
1. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Christensen SB; Skytte DM; Denmeade SR; Dionne C; Møller JV; Nissen P; Isaacs JT
Anticancer Agents Med Chem; 2009 Mar; 9(3):276-94. PubMed ID: 19275521
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
3. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
4. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
5. Targeting Toxins toward Tumors.
Franzyk H; Christensen SB
Molecules; 2021 Feb; 26(5):. PubMed ID: 33673582
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
[TBL] [Abstract][Full Text] [Related]
8. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Christensen SB; Andersen A; Kromann H; Treiman M; Tombal B; Denmeade S; Isaacs JT
Bioorg Med Chem; 1999 Jul; 7(7):1273-80. PubMed ID: 10465403
[TBL] [Abstract][Full Text] [Related]
9. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Denmeade SR; Isaacs JT
Cancer Biol Ther; 2005 Jan; 4(1):14-22. PubMed ID: 15662118
[TBL] [Abstract][Full Text] [Related]
10. Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.
Zimmermann T; Christensen SB; Franzyk H
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914143
[TBL] [Abstract][Full Text] [Related]
11. Total synthesis of five thapsigargins: guaianolide natural products exhibiting sub-nanomolar SERCA inhibition.
Andrews SP; Ball M; Wierschem F; Cleator E; Oliver S; Högenauer K; Simic O; Antonello A; Hünger U; Smith MD; Ley SV
Chemistry; 2007; 13(20):5688-712. PubMed ID: 17508363
[TBL] [Abstract][Full Text] [Related]
12. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid.
Kahnberg P; Lucke AJ; Glenn MP; Boyle GM; Tyndall JD; Parsons PG; Fairlie DP
J Med Chem; 2006 Dec; 49(26):7611-22. PubMed ID: 17181145
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
15. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
16. Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Quynh Doan NT; Christensen SB
Curr Pharm Des; 2015; 21(38):5501-17. PubMed ID: 26429715
[TBL] [Abstract][Full Text] [Related]
17. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
Qin X; Fang L; Zhao J; Gou S
Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
[TBL] [Abstract][Full Text] [Related]
18. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
20. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
Akinboye ES; Rogers OC; Isaacs JT
Prostate; 2018 Jun; 78(9):655-663. PubMed ID: 29572902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
